Actionable news
0
All posts from Actionable news
Actionable news in VRX: VALEANT PHARMACEUTICALS INTERNATIONAL,

PHARMING Amends RUCONEST Distribution Agreement with SOBI

LEIDEN, the Netherlands, July 14, 2016 /PRNewswire/ --

Pharming To Directly Commercialise RUCONEST in 21 Additional Western European, North African And Middle-Eastern Markets

Pharming Group NV ("Pharming" or "the Company") (PHARM.AS) and Swedish Orphan Biovitrum AB (publ) or "Sobi" (SS:SOBI), today announced an amendment of the RUCONEST® distribution agreement signed in 2009 with Swedish Orphan Biovitrum AB (publ) (Sobi).

In addition to Austria, Germany and Netherlands, Pharming will market RUCONEST® directly into an additional 21 countries, effective 1 October 2016. These countries include Algeria, Andorra, Bahrain, Belgium, France, Ireland, Jordan, Kuwait, Lebanon, Luxembourg, Morocco, Oman, Portugal, Qatar, Syria, Spain, Switzerland, Tunisia, United Arab Emirates, United Kingdom and Yemen.

To support the commercialization, Pharming will expand the current small European team of experienced HAE marketing and medical affairs specialists.

To ensure a seamless hand-over and guarantee the continuous availability of RUCONEST® to patients, Sobi will continue to deliver RUCONEST® and continue the drug safety monitoring and reporting, until 1 October 2016.

Sijmen de Vries, Pharming's CEO, commented, "Extension of our direct commercialization of RUCONEST® into these additional 21 markets is a further step towards our goal of becoming a specialty pharma company with significant commercial infrastructure to be able to fully benefit from the added value of bringing our products to patients. Despite RUCONEST® sales in these important markets being modest, this move is expected to have a positive impact on our financial performance as we will be able to improve the margin from sales with every vial of RUCONEST® sold.

About Pharming Group NV

Pharming is a specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs. Pharming's lead product, RUCONEST® (conestat alfa) is a...


More